{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:57:34Z","timestamp":1793044654392,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study aimed to examine amyloid-\u03b2 (A\u03b2) and tau (AT) biological stages, plasma biomarkers, and cognitive trajectories according to AT stages in Alzheimer\u2019s disease-related cognitive impairment (ADCI), subcortical vascular cognitive impairment (SVCI), and frontotemporal dementia (FTD). A total of 275 participants (42 cognitively unimpaired [CU], 132 ADCI, 73 SVCI, and 28 FTD) underwent A\u03b2 and tau positron emission tomography for assessment of AT stages. Participants with cognitive impairment (ADCI, SVCI, and FTD) were classified according to clinical stages of mild cognitive impairment or dementia. Plasma biomarkers were analysed, and cognitive trajectories were assessed using mixed-effects models over 6.1 years. SVCI and FTD showed more advanced clinical stages than ADCI at equivalent AT stages. SVCI participants had higher plasma glial fibrillary acidic protein (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.012) and neurofilament light chain (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.025) than CU participants in the A\u2009\u2212\u2009T\u2212 stage. In the A\u2009\u2212\u2009T\u2212 stage, SVCI (\u03b2 = -0.738,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.002) and FTD (\u03b2 = -4.016,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) showed faster cognitive decline than CU, but not ADCI. In the A\u2009+\u2009T\u2009\u2212\u2009stage, ADCI (\u03b2 = -0.634,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.005) and SVCI (\u03b2 = -0.690,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.006) showed faster decline than CU. In the A\u2009+\u2009T\u2009+\u2009stage, only ADCI exhibited significantly faster decline than CU (\u03b2 = -1.856,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.008). Distinct plasma biomarker profiles and cognitive trajectories characterise ADCI, SVCI, and FTD across AT classification, highlighting the heterogeneity in pathophysiological mechanisms across dementia types.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-30117-y","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:54:39Z","timestamp":1765475679000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrative analysis of AT classification, plasma biomarkers, and cognitive trajectories across diverse dementia syndromes"],"prefix":"10.1038","volume":"16","author":[{"given":"Jihwan","family":"Yun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Young","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gonzalez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daeun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyeon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongki","family":"Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hwan","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Yong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Hyun","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Ho","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duk L.","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Won","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyemin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"30117_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA research framework: toward a biological definition of alzheimer\u2019s disease. Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc. 14, 535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018 (2018).","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"30117_CR2","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack, C. R. Jr. et al. Revised criteria for diagnosis and staging of alzheimer\u2019s disease: alzheimer\u2019s association workgroup. Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc. 20, 5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859 (2024).","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"30117_CR3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/RLU.0000000000005457","volume":"49","author":"H Jang","year":"2024","unstructured":"Jang, H. et al. Distinct cognitive trajectories according to amyloid positivity in Non-Alzheimer disease dementias. Clin. Nucl. Med. 49, 1073\u20131078. https:\/\/doi.org\/10.1097\/RLU.0000000000005457 (2024).","journal-title":"Clin. Nucl. Med."},{"key":"30117_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00259-007-0523-1","volume":"35","author":"H Engler","year":"2008","unstructured":"Engler, H. et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur. J. Nucl. Med. Mol. Imaging. 35, 100\u2013106. https:\/\/doi.org\/10.1007\/s00259-007-0523-1 (2008).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"30117_CR5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1053\/j.sult.2020.08.011","volume":"41","author":"PA Rowley","year":"2020","unstructured":"Rowley, P. A. et al. Amyloid and Tau PET imaging of alzheimer disease and other neurodegenerative conditions. Semin Ultrasound CT MR. 41, 572\u2013583. https:\/\/doi.org\/10.1053\/j.sult.2020.08.011 (2020).","journal-title":"Semin Ultrasound CT MR"},{"key":"30117_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1212\/WNL.0b013e318221acee","volume":"77","author":"JH Lee","year":"2011","unstructured":"Lee, J. H. et al. Identification of pure subcortical vascular dementia using 11\u00a0C-Pittsburgh compound B. Neurology 77, 18\u201325. https:\/\/doi.org\/10.1212\/WNL.0b013e318221acee (2011).","journal-title":"Neurology"},{"key":"30117_CR7","doi-asserted-by":"publisher","first-page":"e2201","DOI":"10.1212\/WNL.0000000000011833","volume":"96","author":"SH Kang","year":"2021","unstructured":"Kang, S. H. et al. Amyloid positivity in the Alzheimer\/Subcortical-Vascular spectrum. Neurology 96, e2201\u2013e2211. https:\/\/doi.org\/10.1212\/WNL.0000000000011833 (2021).","journal-title":"Neurology"},{"key":"30117_CR8","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1093\/brain\/aww148","volume":"139","author":"HJ Kim","year":"2016","unstructured":"Kim, H. J. et al. Relative impact of amyloid-beta, lacunes, and downstream imaging markers on cognitive trajectories. Brain 139, 2516\u20132527. https:\/\/doi.org\/10.1093\/brain\/aww148 (2016).","journal-title":"Brain"},{"key":"30117_CR9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1212\/WNL.0000000000002097","volume":"85","author":"BS Ye","year":"2015","unstructured":"Ye, B. S. et al. Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. Neurology 85, 1687\u20131693. https:\/\/doi.org\/10.1212\/WNL.0000000000002097 (2015).","journal-title":"Neurology"},{"key":"30117_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1136\/jnnp-2023-331603","volume":"95","author":"MY Chun","year":"2023","unstructured":"Chun, M. Y. et al. Emerging role of vascular burden in AT(N) classification in individuals with alzheimer\u2019s and concomitant cerebrovascular burdens. J. Neurol. Neurosurg. Psychiatry. 95, 44\u201351. https:\/\/doi.org\/10.1136\/jnnp-2023-331603 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"30117_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3233\/JAD-200680","volume":"78","author":"H Jang","year":"2020","unstructured":"Jang, H. et al. The impact of Amyloid-beta or Tau on cognitive change in the presence of severe cerebrovascular disease. J. Alzheimers Dis. 78, 573\u2013585. https:\/\/doi.org\/10.3233\/JAD-200680 (2020).","journal-title":"J. Alzheimers Dis."},{"key":"30117_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.dadm.2017.05.005","volume":"9","author":"RH Tan","year":"2017","unstructured":"Tan, R. H. et al. Assessment of amyloid beta in pathologically confirmed frontotemporal dementia syndromes. Alzheimers Dement.\u00a0 9, 10\u201320. https:\/\/doi.org\/10.1016\/j.dadm.2017.05.005 (2017).","journal-title":"Alzheimers Dement.\u00a0"},{"key":"30117_CR13","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele, R. et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 313, 1939\u20131949. https:\/\/doi.org\/10.1001\/jama.2015.4669 (2015).","journal-title":"JAMA"},{"key":"30117_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/jpm11010047","volume":"11","author":"G Giacomucci","year":"2021","unstructured":"Giacomucci, G. et al. Matching clinical diagnosis and amyloid biomarkers in alzheimer\u2019s disease and frontotemporal dementia. J. Personalized Med. 11, 47. https:\/\/doi.org\/10.3390\/jpm11010047 (2021).","journal-title":"J. Personalized Med."},{"key":"30117_CR15","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1212\/WNL.0b013e31823b9c5e","volume":"77","author":"GD Rabinovici","year":"2011","unstructured":"Rabinovici, G. D. et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 77, 2034\u20132042. https:\/\/doi.org\/10.1212\/WNL.0b013e31823b9c5e (2011).","journal-title":"Neurology"},{"key":"30117_CR16","doi-asserted-by":"publisher","first-page":"fcae075","DOI":"10.1093\/braincomms\/fcae075","volume":"6","author":"M Kubota","year":"2024","unstructured":"Kubota, M. et al. In vivo PET classification of Tau pathologies in patients with frontotemporal dementia. Brain Commun. 6, fcae075. https:\/\/doi.org\/10.1093\/braincomms\/fcae075 (2024).","journal-title":"Brain Commun."},{"key":"30117_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3988\/jcn.2022.18.4.401","volume":"18","author":"SA Park","year":"2022","unstructured":"Park, S. A., Jang, Y. J., Kim, M. K., Lee, S. M. & Moon, S. Y. Promising blood biomarkers for clinical use in alzheimer\u2019s disease: A focused update. J. Clin. Neurol. 18, 401\u2013409. https:\/\/doi.org\/10.3988\/jcn.2022.18.4.401 (2022).","journal-title":"J. Clin. Neurol."},{"key":"30117_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.12779\/dnd.2024.23.4.212","volume":"23","author":"H Jang","year":"2024","unstructured":"Jang, H. et al. Korea-Registries to overcome dementia and accelerate dementia research (K-ROAD): A cohort for dementia research and Ethnic-Specific insights. Dement. Neurocognitive Disorders. 23, 212\u2013223. https:\/\/doi.org\/10.12779\/dnd.2024.23.4.212 (2024).","journal-title":"Dement. Neurocognitive Disorders"},{"key":"30117_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1037\/1040-3590.3.2.168","volume":"3","author":"KJ Christensen","year":"1991","unstructured":"Christensen, K. J., Multhaup, K. S., Nordstrom, S. & Voss, K. A cognitive battery for dementia: development and measurement characteristics. Psychol. Assess. 3, 168\u2013174. https:\/\/doi.org\/10.1037\/1040-3590.3.2.168 (1991).","journal-title":"Psychol. Assess."},{"key":"30117_CR20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3346\/jkms.2010.25.7.1071","volume":"25","author":"HJ Ahn","year":"2010","unstructured":"Ahn, H. J. et al. Seoul neuropsychological screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J. Korean Med. Sci. 25, 1071\u20131076. https:\/\/doi.org\/10.3346\/jkms.2010.25.7.1071 (2010).","journal-title":"J. Korean Med. Sci."},{"key":"30117_CR21","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1212\/wnl.43.9.1683","volume":"43","author":"F Fazekas","year":"1993","unstructured":"Fazekas, F. et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 43, 1683\u20131689. https:\/\/doi.org\/10.1212\/wnl.43.9.1683 (1993).","journal-title":"Neurology"},{"key":"30117_CR22","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.06.002","volume":"23","author":"Y Noh","year":"2014","unstructured":"Noh, Y. et al. A new classification system for ischemia using a combination of deep and periventricular white matter hyperintensities. J. Stroke Cerebrovasc. Dis. 23, 636\u2013642. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2013.06.002 (2014).","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"30117_CR23","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456\u20132477. https:\/\/doi.org\/10.1093\/brain\/awr179 (2011).","journal-title":"Brain"},{"key":"30117_CR24","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006\u20131014. https:\/\/doi.org\/10.1212\/WNL.0b013e31821103e6 (2011).","journal-title":"Neurology"},{"key":"30117_CR25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong, M. J. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496\u2013503. https:\/\/doi.org\/10.1212\/WNL.0b013e31827f0fd1 (2013).","journal-title":"Neurology"},{"key":"30117_CR26","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov. Disord. 32, 853\u2013864. https:\/\/doi.org\/10.1002\/mds.26987 (2017).","journal-title":"Mov. Disord"},{"key":"30117_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/17482960802654364","volume":"10","author":"MJ Strong","year":"2009","unstructured":"Strong, M. J. et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 10, 131\u2013146. https:\/\/doi.org\/10.1080\/17482960802654364 (2009).","journal-title":"Amyotroph. Lateral Scler."},{"key":"30117_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert, M. S. et al. The diagnosis of mild cognitive impairment due to alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc. 7, 270\u2013279. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008 (2011).","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"30117_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc. 7, 263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005 (2011).","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"30117_CR30","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1007\/s00259-019-04596-x","volume":"47","author":"SH Cho","year":"2020","unstructured":"Cho, S. H. et al. A new centiloid method for (18)F-florbetaben and (18)F-flutemetamol PET without conversion to PiB. Eur. J. Nucl. Med. Mol. Imaging. 47, 1938\u20131948. https:\/\/doi.org\/10.1007\/s00259-019-04596-x (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"30117_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13195-022-01099-0","volume":"14","author":"SJ Kim","year":"2022","unstructured":"Kim, S. J. et al. Development and clinical validation of CT-based regional modified centiloid method for amyloid PET. Alzheimers Res. Ther. 14, 157. https:\/\/doi.org\/10.1186\/s13195-022-01099-0 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"30117_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.12779\/dnd.2025.24.2.135","volume":"24","author":"S Park","year":"2025","unstructured":"Park, S. et al. Establishing regional A\u03b2 cutoffs and exploring subgroup prevalence across cognitive stages using BeauBrain Amylo\u00ae. Dement. Neurocognitive Disorders. 24, 135\u2013146 (2025).","journal-title":"Dement. Neurocognitive Disorders"},{"key":"30117_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.12779\/dnd.2024.23.3.117","volume":"23","author":"J Kim","year":"2024","unstructured":"Kim, J., Jahng, S., Kim, S. & Kang, Y. A. Comparison of item characteristics and test information between the K-MMSE\u2009~\u20092:SV and K-MMSE. Dement. Neurocognitive Disorders. 23, 117\u2013126. https:\/\/doi.org\/10.12779\/dnd.2024.23.3.117 (2024).","journal-title":"Dement. Neurocognitive Disorders"},{"key":"30117_CR34","doi-asserted-by":"publisher","first-page":"e14526","DOI":"10.1002\/alz.14526","volume":"21","author":"H Jang","year":"2025","unstructured":"Jang, H. et al. Differential roles of alzheimer\u2019s disease plasma biomarkers in Stepwise biomarker-guided diagnostics. Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc. 21, e14526. https:\/\/doi.org\/10.1002\/alz.14526 (2025).","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"30117_CR35","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/brain\/awae346","volume":"148","author":"N Warmenhoven","year":"2025","unstructured":"Warmenhoven, N. et al. A comprehensive head-to-head comparison of key plasma phosphorylated Tau 217 biomarker tests. Brain 148, 416\u2013431. https:\/\/doi.org\/10.1093\/brain\/awae346 (2025).","journal-title":"Brain"},{"key":"30117_CR36","doi-asserted-by":"publisher","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","volume":"102","author":"J Therriault","year":"2024","unstructured":"Therriault, J. et al. Comparison of two plasma p-tau217 assays to detect and monitor alzheimer\u2019s pathology. EBioMedicine 102, 105046. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105046 (2024).","journal-title":"EBioMedicine"},{"key":"30117_CR37","doi-asserted-by":"publisher","first-page":"e12928","DOI":"10.1111\/bpa.12928","volume":"31","author":"R Waller","year":"2021","unstructured":"Waller, R. et al. Heterogeneity of cellular inflammatory responses in ageing white matter and relationship to alzheimer\u2019s and small vessel disease pathologies. Brain Pathol. 31, e12928. https:\/\/doi.org\/10.1111\/bpa.12928 (2021).","journal-title":"Brain Pathol."},{"key":"30117_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081869","author":"A Huss","year":"2022","unstructured":"Huss, A. et al. Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease. Biomed. https:\/\/doi.org\/10.3390\/biomedicines10081869 (2022).","journal-title":"Biomed."},{"key":"30117_CR39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11357-023-00888-1","volume":"46","author":"ACE van Gennip","year":"2024","unstructured":"van Gennip, A. C. E. et al. Associations of plasma NfL, GFAP, and t-tau with cerebral small vessel disease and incident dementia: longitudinal data of the AGES-Reykjavik study. Geroscience 46, 505\u2013516. https:\/\/doi.org\/10.1007\/s11357-023-00888-1 (2024).","journal-title":"Geroscience"},{"key":"30117_CR40","doi-asserted-by":"publisher","first-page":"e903","DOI":"10.1212\/WNL.0000000000013229","volume":"98","author":"AE Fohner","year":"2022","unstructured":"Fohner, A. E. et al. Association of serum neurofilament light chain concentration and MRI findings in older adults: the cardiovascular health study. Neurology 98, e903\u2013e911. https:\/\/doi.org\/10.1212\/WNL.0000000000013229 (2022).","journal-title":"Neurology"},{"key":"30117_CR41","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/jnnp-2020-325681","volume":"92","author":"M Egle","year":"2021","unstructured":"Egle, M. et al. Neurofilament light chain predicts future dementia risk in cerebral small vessel disease. J. Neurol. Neurosurg. Psychiatry. 92, 582\u2013589. https:\/\/doi.org\/10.1136\/jnnp-2020-325681 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"30117_CR42","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1161\/STROKEAHA.120.030302","volume":"52","author":"Y Qu","year":"2021","unstructured":"Qu, Y. et al. Association of plasma neurofilament light with small vessel disease burden in nondemented elderly: A longitudinal study. Stroke 52, 896\u2013904. https:\/\/doi.org\/10.1161\/STROKEAHA.120.030302 (2021).","journal-title":"Stroke"},{"key":"30117_CR43","doi-asserted-by":"publisher","first-page":"e12291","DOI":"10.1002\/dad2.12291","volume":"14","author":"D Shir","year":"2022","unstructured":"Shir, D. et al. Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of alzheimer\u2019s disease and vascular pathology. Alzheimers Dement. (Amst. 14, e12291. https:\/\/doi.org\/10.1002\/dad2.12291 (2022).","journal-title":"Alzheimers Dement. (Amst"},{"key":"30117_CR44","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41593-020-00783-4","volume":"24","author":"C Escartin","year":"2021","unstructured":"Escartin, C. et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat. Neurosci. 24, 312\u2013325. https:\/\/doi.org\/10.1038\/s41593-020-00783-4 (2021).","journal-title":"Nat. Neurosci."},{"key":"30117_CR45","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel, C. et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and Meta-analysis. JAMA Neurol. 76, 1035\u20131048. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1534 (2019).","journal-title":"JAMA Neurol."},{"key":"30117_CR46","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/nan.12338","volume":"43","author":"CJ Garwood","year":"2017","unstructured":"Garwood, C. J. et al. Astrocytes in alzheimer\u2019s disease and other age-associated dementias: a supporting player with a central role. Neuropathol. Appl. Neurobiol. 43, 281\u2013298. https:\/\/doi.org\/10.1111\/nan.12338 (2017). Review.","journal-title":"Neuropathol. Appl. Neurobiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30117-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:38:34Z","timestamp":1767706714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30117-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["30117"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-30117-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The institutional review board of Samsung Medical Center (No. 2020\u201312\u2013177) approved this study. Informed consent was obtained from all subjects and\/or their legal guardian(s). All methods were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants and, when necessary, from their legal guardians if participants were unable to provide consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"610"}}